EVQLV Joins BAJ Accelerator

May 23, 2020 | Press Releases | 0 comments

Daniel Gigante

EVQLV is excited to announce we’ve joined the BAJ Accelerator. The accelerator runs from Monday, May 18th to Friday, May 22nd. We’re confident BAJ will provide the necessary support and resources we need to reach the next level in our journey.

About BAJ: BAJ Accelerator is for Startups at a Pre-Seed level up to Series A who are seeking funding. This program includes influential networking opportunities, targeted coaching, real-time customer interviews, collaboration sessions, training and full-day presentations from top- level executives from around the globe. Topics vary across sectors including technology, legal, finance, banking, investment & consulting to dynamic dealmakers and active investors.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview¬†of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest